Drug Profile
ET 019003
Alternative Names: Anti-CD19 ARTEMIS™ Therapy; Anti-CD19 chimeric antigen receptor T cell therapy - Eureka Therapeutics; Anti-CD19 immunotherapy - Eureka Therapeutics; ET019003; ET019003-T cellsLatest Information Update: 20 Oct 2022
Price :
$50
*
At a glance
- Originator Eureka Therapeutics
- Developer Eureka Therapeutics; Imugene
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Preclinical Solid tumours
Most Recent Events
- 06 Oct 2022 Preclinical trials in Solid tumours in China (IV)(Eureka Therapeutics pipeline, October 2022)
- 06 Oct 2022 Anti-CD19 CAR T cell therapy is still in phase-I trials for Diffuse large B cell lymphoma, Non-Hodgkin's lymphoma and Precursor B-cell lymphoblastic leukaemia-lymphoma in China (Eureka Therapeutics pipeline, October 2022)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Second-line therapy or greater) in China (IV, Infusion)